참여증명서 발급문의하기사이트맵

ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.

전체 2295건의 자료가 검색되었습니다.

Excel Download

코로나19(COVID19) 임상시험 현황
No. Status Study Title Conditions Interventions Phase Sponsor/Collaborators Funder Type Number Enrolled Sex Age Locations
2267 Active, not recruiting A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) COVID-19 Biological: Recombinant COVID-19 vaccine (Sf9 cells)
Other: Placebo control
Phase 3 WestVac Biopharma Co., Ltd., West China Hospital INDUSTRY 40000 All 18 Years Puskesmas Ciketingudik, Bekasi, Jiangsu, Indonesia
Permata Hospital, Bekasi, Indonesia
Brawijaya University Hospital, Malang, Indonesia
Universitas Muhammadiyah Malang Hospital, Malang, Indonesia
Airlangga University Hospital, Surabaya, Indonesia
Husada Utama Hospital, Surabaya, Indonesia
Moi Teaching and Referral Hospital,Eldoret (MTRH), Eldoret, Kenya
KAVI-Institute of Clinical Research, University of Nairobi, Nairobi, Kenya
Hospital General Dr. Manuel Gea Gonzalez, Ciudad de Mexico, Mexico
Invesclinic MX, Ciudad de Mexico, Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico
Centro de Investigacion Clinica y medicina traslacional (CIMeT), Guadalajara, Mexico
Clinica de Enfermedades Cronicas y de Procedimientos Especiales, Morelia, Mexico
SMIQ,S de R.L. de C.V., Queretaro, Mexico
FS Scientia Pharma SA de CV, San Luis Potosi, Mexico
Bharatpur Hospital, Kathmandu, Nepal
Perpetual Succour Hospital - The Research Institute, Cebu City, Philippines
De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines
The Medical City - Iloilo, Iloilo City, Philippines
West Visayas State University Medical Center, Iloilo City, Philippines
Tropical Disease Foundation, Makati City, Philippines
Makati Medical Center, Makati City, Philippines
Quirino Memorial Medical Center, Quezon City, Philippines
St Luke Medical Centre - BGC, Taguig, Philippines
2266 Unknown status A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 COVID-19 Vaccine Biological: MVC-COV1901(3 Months)
Biological: MVC-COV1901(6 Months)
Phase 4 Taoyuan General Hospital, Medigen Vaccine Biologics Corp. OTHER_GOV 200 All 20 Years ~ 64 Years Taoyuan General Hospital, Taoyuan, Taiwan
2265 Completed A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults Covid19 Vaccine Biological: Homologous boost schedule
Biological: Heterologous boost schedule
Phase 4 National Taiwan University Hospital OTHER 220 All 20 Years ~ 69 Years National Taiwan University Hospital, Taipei, Taiwan
2264 Active, not recruiting A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated Covid19 Biological: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
Biological: 2 doses of vaccine
Phase 4 China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. INDUSTRY 4400 All 3 Years Yanjin County Center for Disease Control and Prevention, Xinxiang, Henan, China
2263 Recruiting A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial Chronic Fatigue Syndrome Drug: Fluvoxamine Maleate 100 MG
Drug: Placebo
Drug: Metformin Extended Release Oral Tablet
Phase 3 Cardresearch OTHER 1500 All 18 Years CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil
City of Brumadinho, Brumadinho, Minas Gerais, Brazil
Governador Valadares City Public Health Authority, Governador Valadares, Minas Gerais, Brazil
City of Ibirite Public Health Authority, Ibirite, Minas Gerais, Brazil
Sociedade Padrao de Educacao Superior, Montes Claros, Minas Gerais, Brazil
Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil
2262 Unknown status A Multi-center,Randomized,Double-blind,Placebo-controlled,Phase 3 Study Evaluating Favipiravir in Treatment of COVID19 COVID-19 Drug: Favipiravir
Other: Placebo
Phase 3 Zhejiang Hisun Pharmaceutical Co. Ltd., Opera CRO, a TIGERMED Group Company INDUSTRY 256 All 18 Years ~ 75 Years The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Shangcheng District, China
Peking University First Hospital, Beijing, Xicheng District, China
Department of Internal Medicine Pneumology and infectious diseases Neukolln Clinic, Berlin, Germany
Medical clinic and polyclinic IV Hospital of the University of Munich, Munchen, Germany
Infectious Diseases Hospital Cluj-Napoca, Cluj-Napoca, Cluj, Romania
National Institute of Infectious Diseases "Prof.Dr.Matei Bals", Bucharest, Ilfov, Romania
"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timisoara, Timis, Romania
"Dr.Victor Babes" Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi?oara, Timis, Romania
Dr.Victor Babes Infectious Diseases and Pneumoftiziology Clinical Hospital Timisoara, Timi?oara, Timis, Romania
Emergency County Hospital "Pius Brinzeu"Timisoara, Timi?oara, Timis, Romania
2261 Completed A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2) COVID-19 Drug: Azithromycin Capsule Phase 3 University of Oxford, Pfizer OTHER 298 All 19 Years Horton General Hospital, Banbury, Oxfordshire, United Kingdom
John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom
Ninewells Hospital, Dundee, Scotland, United Kingdom
Birmingham City Hospital, Birmingham, United Kingdom
Sandwell General Hospital, West Bromwich, United Kingdom